Insider · CIK 0001192591

HOMCY CHARLES J

Reports to the SEC for 12 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001192591

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-22	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+3,990 sh	—	—	919,876
2026-06-22	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,277 sh	—	—	5,277
2026-06-20	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−788 sh	$66.27	−$52.2K	915,886
2026-06-08	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2026-05-04	MAZEMaze Therapeutics, Inc.G Gift	Director	GGift	−7,422 sh	—	—	31,113
2025-11-19	MAZEMaze Therapeutics, Inc.J Other	Director	JOther	+1,489 sh	—	—	31,113
2025-10-23	MAZEMaze Therapeutics, Inc.G Gift	Director	GGift	−28.4K sh	—	—	29,624
2025-09-22	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2025-08-11	BBIOBridgeBio Pharma, Inc.S Sale	Director	SSale	−50K sh	$48.00	−$2.4M	916,674
2025-08-08	BBIOBridgeBio Pharma, Inc.S Sale	Director	SSale	−58.3K sh	$46.64	−$2.72M	966,674
2025-08-08	BBIOBridgeBio Pharma, Inc.S Sale	Director	SSale	−192K sh	$45.87	−$8.79M	1,025,012
2025-06-27	BBIOBridgeBio Pharma, Inc.G Gift	Director	GGift	−20K sh	—	—	1,216,674
2025-06-20	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,425 sh	—	—	8,425
2025-06-20	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+6,589 sh	—	—	1,236,674
2025-02-03	MAZEMaze Therapeutics, Inc.C Conversion	Director	CConversion	+8,807 sh	—	—	37,330
2025-02-03	MAZEMaze Therapeutics, Inc. · Series D-1 Preferred StockC Conversion	Director	CConversion	−71.6K sh	—	—	0
2025-02-03	MAZEMaze Therapeutics, Inc.C Conversion	Director	CConversion	+7,422 sh	—	—	7,422
2025-02-03	MAZEMaze Therapeutics, Inc. · Series C Preferred StockC Conversion	Director	CConversion	−169K sh	—	—	0
2025-02-03	MAZEMaze Therapeutics, Inc.C Conversion	Director	CConversion	+20.7K sh	—	—	58,047
2025-02-03	MAZEMaze Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−72.7K sh	—	—	0
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−80.4K sh	—	—	0
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+46.7K sh	—	—	46,675
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45.6K sh	—	—	45,638
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,704 sh	—	—	0
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,704 sh	—	—	5,704
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+80.4K sh	—	—	80,385
2024-12-09	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−46.7K sh	—	—	0
2024-11-26	MAZEMaze Therapeutics, Inc. · Series D-1 Preferred StockC Conversion	Director	CConversion	+71.6K sh	—	—	7,422
2024-11-26	MAZEMaze Therapeutics, Inc. · 8% Convertible Note due 2026C Conversion	Director	CConversion	—	$78961.64	—	—
2024-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+26K sh	—	—	26,014
2024-02-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,760 sh	—	—	0
2024-02-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,509 sh	$37.21	−$56.1K	1,230,085
2024-02-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,231,594
2023-11-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,228,297
2023-11-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,301 sh	$28.86	−$37.5K	1,226,996
2023-11-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,760 sh	—	—	3,760
2023-08-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,301 sh	$29.80	−$38.8K	1,224,537
2023-08-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,760 sh	—	—	7,520
2023-08-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,225,838
2023-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+51.5K sh	—	—	51,501
2023-05-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,759 sh	—	—	11,280
2023-05-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,300 sh	$14.09	−$18.3K	1,220,827
2023-05-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,759 sh	—	—	1,222,127
2023-02-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,760 sh	—	—	15,039
2023-02-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,534 sh	$12.64	−$19.4K	1,218,368
2023-02-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,219,902
2022-11-16	BBIOBridgeBio Pharma, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,760 sh	—	—	18,799
2022-11-16	BBIOBridgeBio Pharma, Inc.F Tax Payment	Director	FTax Payment	−1,301 sh	$9.64	−$12.5K	1,214,251
2022-11-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,215,552
2022-08-16	BBIOBridgeBio Pharma, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,760 sh	—	—	1,210,742

Recent filings

Accepted (ET)
Jun 244
HOMCY CHARLES J0001470831-26-000633
SEC(opens sec.gov)
Jun 234
HOMCY CHARLES J0001470831-26-000569
SEC(opens sec.gov)
Jun 104
HOMCY CHARLES J0001192591-26-000004
SEC(opens sec.gov)
May 64
HOMCY CHARLES J0001192591-26-000002
SEC(opens sec.gov)
Nov 214
HOMCY CHARLES J0001192591-25-000010
SEC(opens sec.gov)
Oct 274
HOMCY CHARLES J0001192591-25-000008
SEC(opens sec.gov)
Sep 244
HOMCY CHARLES J0001192591-25-000005
SEC(opens sec.gov)
Aug 124
HOMCY CHARLES J0000950170-25-107510
SEC(opens sec.gov)
Jun 304
HOMCY CHARLES J0000950170-25-091764
SEC(opens sec.gov)
Jun 244
HOMCY CHARLES J0000950170-25-089648
SEC(opens sec.gov)
Feb 44
HOMCY CHARLES J0001415889-25-002956
SEC(opens sec.gov)

Companies

Address

C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250

PALO ALTO, CA, 94304